Real World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis: Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Alexander Egeberg; Giampiero Girolomoni; Steven R Feldman; Marc-Alexander Radtke; José Manuel Carrascosa; Jeehoon Ghil; Jung Won Keum; Jieun Lee; Hyoryeong Seo

Real World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis: Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Alexander Egeberg, Giampiero Girolomoni, Steven R Feldman, Marc-Alexander Radtke, José Manuel Carrascosa, Jeehoon Ghil, Jung Won Keum, Jieun Lee, Hyoryeong Seo

Dermatology and Allergy

Abstract

Psoriasis is a chronic, systemic, inflammatory skin disease with a risk of comorbidities and a potential high impact on patients’ quality of life.

Original language	English
Journal	Journal of drugs in dermatology : JDD
Volume	19
Issue number	3
Pages (from-to)	316-318
Number of pages	3
ISSN	1545-9616
Publication status	Published - 1 Mar 2020

Cite this

Real World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis : Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR). / Egeberg, Alexander; Girolomoni, Giampiero; Feldman, Steven R et al.

In: Journal of drugs in dermatology : JDD, Vol. 19, No. 3, 01.03.2020, p. 316-318.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{553c4fc6a28b4a8aaa8cf67b5ec6f523,

title = "Real World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis: Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR)",

abstract = "Psoriasis is a chronic, systemic, inflammatory skin disease with a risk of comorbidities and a potential high impact on patients’ quality of life.",

author = "Alexander Egeberg and Giampiero Girolomoni and Feldman, {Steven R} and Marc-Alexander Radtke and Carrascosa, {Jos{\'e} Manuel} and Jeehoon Ghil and Keum, {Jung Won} and Jieun Lee and Hyoryeong Seo",

year = "2020",

month = mar,

day = "1",

language = "English",

volume = "19",

pages = "316--318",

journal = "Journal of Drugs in Dermatology",

issn = "1545-9616",

publisher = "Journal of Drugs in Dermatology",

number = "3",

}

TY - JOUR

T1 - Real World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis

T2 - Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

AU - Egeberg, Alexander

AU - Girolomoni, Giampiero

AU - Feldman, Steven R

AU - Radtke, Marc-Alexander

AU - Carrascosa, José Manuel

AU - Ghil, Jeehoon

AU - Keum, Jung Won

AU - Lee, Jieun

AU - Seo, Hyoryeong

PY - 2020/3/1

Y1 - 2020/3/1

N2 - Psoriasis is a chronic, systemic, inflammatory skin disease with a risk of comorbidities and a potential high impact on patients’ quality of life.

AB - Psoriasis is a chronic, systemic, inflammatory skin disease with a risk of comorbidities and a potential high impact on patients’ quality of life.

M3 - Journal article

C2 - 32550686

VL - 19

SP - 316

EP - 318

JO - Journal of Drugs in Dermatology

JF - Journal of Drugs in Dermatology

SN - 1545-9616

IS - 3

ER -

Real World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis: Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

Abstract

Fingerprint

Cite this